Top

Current Treatment Options in Gastroenterology

Published in:

01-12-2018 | Motility (H Parkman and R Schey, Section Editors)

The Role of Botulinum Toxin Injections for Esophageal Motility Disorders

Authors: Jessica L. Sterling, MD, Ron Schey, MD, Zubair Malik, MD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2018

Abstract

Purpose of review

The advancement of high-resolution esophageal manometry has led to improvement in the diagnosis of esophageal motility disorders. We reviewed the recent medical literature regarding the use of botulinum toxin (BTx) injections in the esophagus and the indications, current outcomes, and reported complications of this therapy.

Recent findings

The response rates of BTx injection therapy vary depending on the esophageal motility disorder. Studies have shown that response is transient in achalasia patients and given the more effective therapies available, it is only recommended in patients who are not surgical candidates. In nonachalasia patients, studies of BTx injections have demonstrated improvement in dysphagia symptoms in patients with spastic disorders, though studies are small and largely retrospective. The available literature showed a variable response to BTx in esophagogastric junction outlet obstruction (EGJOO) and non-cardiac chest pain patients. Despite advances in diagnosing esophageal motility disorders, there is a need for further research in patient selection for esophageal BTx, dose and injection location, and disease-specific outcomes. Placebo-controlled trials are crucial to evaluate BTx efficacy and duration of response.

Summary

Esophageal-directed BTx injections are beneficial in improving dysphagia in spastic motility disorders and in achalasia patients who are elderly or have multiple co-morbidities. There is a lack of evidence to support use in patients with EGJOO and non-cardiac chest pain, or for young or healthy achalasia patients.

• Rohof WOA, Bredenoord AJ. Chicago classification of esophageal motility disorders: lessons learned. Curr Gastroenterol Rep. 2017;19(8):37. https://doi.org/10.1007/s11894-017-0576-7 This review highlights the advancements in diagnosis of esophageal motility disorders.CrossRefPubMedPubMedCentral

Brisinda G, Sivestrini N, Bianco G, Maria G. Treatment of gastrointestinal sphincters spasms with botulinum toxin a. Toxins (Basel). 2015;7(6):1882–916. https://doi.org/10.3390/toxins7061882.CrossRef

Tack J, Zaninotto G. Therapeutic options in oesophageal dysphagia. Nat Rev Gastroenterol Hepatol. 2015;12(6):332–41. https://doi.org/10.1038/nrgastro.2015.45.CrossRefPubMed

Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S et al. The expanding therapeutic utility of botulinum neurotoxins. Toxins (Basel). 2018;10(5). https://doi.org/10.3390/toxins10050208.CrossRefPubMedCentral

• van Hoeij FB, Tack JF, Pandolfino JE, Sternbach JM, Roman S, Smout AJ, et al. Complications of botulinum toxin injections for treatment of esophageal motility disorders†. Dis Esophagus. 2017;30(3):1–5. https://doi.org/10.1111/dote.12491 This is the only analysis that highlights the important complications of esophageal BTX injections.CrossRefPubMed

Roman S, Kahrilas PJ. Distal esophageal spasm. Curr Opin Gastroenterol. 2015;31(4):328–33. https://doi.org/10.1097/MOG.0000000000000187.CrossRefPubMed

Zerbib FM, Roman SM. Current therapeutic options for esophageal motor disorders as defined by the Chicago classification. J Clin Gastroenterol. 2015;49(6):451–60.PubMed

Ratuapli SK, Crowell MD, DiBaise JK, Vela MF, Ramirez FC, Burdick GE, et al. Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids. Am J Gastroenterol. 2015;110(7):979–84. https://doi.org/10.1038/ajg.2015.154.CrossRefPubMed

van Hoeij FB, Smout AJ, Bredenoord AJ. Characterization of idiopathic esophagogastric junction outflow obstruction. Neurogastroenterol Motil. 2015;27(9):1310–6. https://doi.org/10.1111/nmo.12625.CrossRefPubMed

10.

Porter RF, Gyawali CP. Botulinum toxin injection in dysphagia syndromes with preserved esophageal peristalsis and incomplete lower esophageal sphincter relaxation. Neurogastroenterol Motil. 2011;23(2):139–44,e27–8.https://doi.org/10.1111/j.1365-2982.2010.01604.x.CrossRefPubMed

11.

Scherer JR, Kwiatek MA, Soper NJ, Pandolfino JE, Kahrilas PJ. Functional esophagogastric junction obstruction with intact peristalsis: a heterogeneous syndrome sometimes akin to achalasia. J Gastrointest Surg. 2009;13(12):2219–25. https://doi.org/10.1007/s11605-009-0975-7.CrossRefPubMedPubMedCentral

12.

Okeke FC, Raja S, Lynch KL, Dhalla S, Nandwani M, Stein EM et al. What is the clinical significance of esophagogastric junction outflow obstruction? evaluation of 60 patients at a tertiary referral center. Neurogastroenterol Motil. 2017;29(6). https://doi.org/10.1111/nmo.13061.CrossRef

13.

Lynch KL, Yang YX, Metz DC, Falk GW. Clinical presentation and disease course of patients with esophagogastric junction outflow obstruction. Dis Esophagus. 2017;30(6):1–6. https://doi.org/10.1093/dote/dox004.CrossRefPubMed

14.

Clayton SB, Patel R, Richter JE. Functional and anatomic esophagogastic junction outflow obstruction: manometry, timed barium esophagram findings, and treatment outcomes. Clin Gastroenterol Hepatol. 2016;14(6):907–11. https://doi.org/10.1016/j.cgh.2015.12.041.CrossRefPubMed

15.

Pérez-Fernández MT, Santander C, Marinero A, Burgos-Santamaría D, Chavarría-Herbozo C. Characterization and follow-up of esophagogastric junction outflow obstruction detected by high resolution manometry. Neurogastroenterol Motil. 2016;28(1):116–26. https://doi.org/10.1111/nmo.12708.CrossRefPubMed

16.

Marjoux S, Brochard C, Roman S, Gincul R, Pagenault M, Ponchon T, et al. Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases? Dis Esophagus. 2015;28(8):735–41. https://doi.org/10.1111/dote.12282.CrossRefPubMed

17.

Sadowski DC, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil. 2010;22(9):e256–61. https://doi.org/10.1111/j.1365-2982.2010.01511.x.CrossRefPubMed

18.

Schlottmann F, Herbella F, Allaix ME, Patti MG. Modern management of esophageal achalasia: from pathophysiology to treatment. Curr Probl Surg. 2018;55(1):10–37. https://doi.org/10.1067/j.cpsurg.2018.01.001.CrossRefPubMed

19.

Dodds WJ, Stewart ET, Kishk SM, Kahrilas PJ, Hogan WJ. Radiologic amyl nitrite test for distinguishing pseudoachalasia from idiopathic achalasia. AJR Am J Roentgenol. 1986;146(1):21–3. https://doi.org/10.2214/ajr.146.1.21.CrossRefPubMed

20.

Lai CN, Krishnan K, Kim MP, Dunkin BJ, Gaur P. Pseudoachalasia presenting 20 years after Nissen fundoplication: a case report. J Cardiothorac Surg. 2016;11(1):96. https://doi.org/10.1186/s13019-016-0495-y.

21.

Uppal DS, Wang AY. Update on the endoscopic treatments for achalasia. World J Gastroenterol. 2016;22(39):8670–83. https://doi.org/10.3748/wjg.v22.i39.8670.CrossRefPubMedPubMedCentral

22.

Stavropoulos SN, Friedel D, Modayil R, Parkman HP. Diagnosis and management of esophageal achalasia. BMJ. 2016;354:i2785.CrossRefPubMed

23.

Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108(8):1238–49; quiz50. https://doi.org/10.1038/ajg.2013.196.CrossRefPubMed

24.

Campos GM, Vittinghoff E, Rabl C, Takata M, Gadenstätter M, Lin F, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg. 2009;249(1):45–57. https://doi.org/10.1097/SLA.0b013e31818e43ab.CrossRefPubMed

25.

Smith I, Kahaleh M. An update on current management strategies for achalasia and future perspectives. J Clin Gastroenterol. 2018;52(4):277–86. https://doi.org/10.1097/MCG.0000000000000966.CrossRefPubMed

26.

Zaninotto G, Annese V, Costantini M, Del Genio A, Costantino M, Epifani M, et al. Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia. Ann Surg. 2004;239(3):364–70.CrossRefPubMedPubMedCentral

27.

Wang L, Li YM, Li L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig Dis Sci. 2009;54(11):2303–11. https://doi.org/10.1007/s10620-008-0637-8.CrossRefPubMed

28.

Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev. 2014;12:CD005046. https://doi.org/10.1002/14651858.CD005046.pub3.CrossRef

29.

Miller HJ, Neupane R, Fayezizadeh M, Majumder A, Marks JM. POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. Surg Endosc. 2017;31(4):1636–42. https://doi.org/10.1007/s00464-016-5151-z.CrossRefPubMed

30.

Smith CD, Stival A, Howell DL, Swafford V. Endoscopic therapy for achalasia before Heller myotomy results in worse outcomes than Heller myotomy alone. Ann Surg. 2006;243(5):579–84;discussion 84–6. https://doi.org/10.1097/01.sla.0000217524.75529.2d.CrossRefPubMedPubMedCentral

31.

Orenstein SB, Raigani S, Wu YV, Pauli EM, Phillips MS, Ponsky JL, et al. Peroral endoscopic myotomy (POEM) leads to similar results in patients with and without prior endoscopic or surgical therapy. Surg Endosc. 2015;29(5):1064–70. https://doi.org/10.1007/s00464-014-3782-5.CrossRefPubMed

32.

Sharata A, Kurian AA, Dunst CM, Bhayani NH, Reavis KM, Swanström LL. Peroral endoscopic myotomy (POEM) is safe and effective in the setting of prior endoscopic intervention. J Gastrointest Surg. 2013;17(7):1188–92. https://doi.org/10.1007/s11605-013-2193-6.CrossRefPubMed

33.

Ling T, Guo H, Zou X. Effect of peroral endoscopic myotomy in achalasia patients with failure of prior pneumatic dilation: a prospective case-control study. J Gastroenterol Hepatol. 2014;29(8):1609–13. https://doi.org/10.1111/jgh.12570.CrossRefPubMed

34.

Gunasingam N, Perczuk A, Talbot M, Kaffes A, Saxena P. Update on therapeutic interventions for the management of achalasia. J Gastroenterol Hepatol. 2016;31(8):1422–8. https://doi.org/10.1111/jgh.13408.CrossRefPubMed

35.

D’Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis. 2002;34(2):105–10.CrossRefPubMed

36.

Khalaf M, Chowdhary S, Elias PS, Castell D. Distal esophageal spasm: a review. Am J Med. 2018;131:1034–40. https://doi.org/10.1016/j.amjmed.2018.02.031.CrossRefPubMed

37.

De Schepper HU, Smout AJ, Bredenoord AJ. Distal esophageal spasm evolving to achalasia in high resolution. Clin Gastroenterol Hepatol. 2014;12(2):A25–6. https://doi.org/10.1016/j.cgh.2013.08.035.CrossRefPubMed

38.

Fontes LH, Herbella FA, Rodriguez TN, Trivino T, Farah JF. Progression of diffuse esophageal spasm to achalasia: incidence and predictive factors. Dis Esophagus. 2013;26(5):470–4. https://doi.org/10.1111/j.1442-2050.2012.01377.x.CrossRefPubMed

39.

Khatami SS, Khandwala F, Shay SS, Vaezi MF. Does diffuse esophageal spasm progress to achalasia? A prospective cohort study. Dig Dis Sci. 2005;50(9):1605–10. https://doi.org/10.1007/s10620-005-2903-3.CrossRefPubMed

40.

Roman S, Kahrilas PJ. Management of spastic disorders of the esophagus. Gastroenterol Clin N Am. 2013;42(1):27–43. https://doi.org/10.1016/j.gtc.2012.11.002.CrossRef

41.

• Vanuytsel T, Bisschops R, Farré R, Pauwels A, Holvoet L, Arts J, et al. Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol. 2013;11(9):1115–21.e2. https://doi.org/10.1016/j.cgh.2013.03.021 This is the only double-blinded, placebo-controlled trial to evaluate BTX injection therapy for nonachalasia motility disorders.CrossRefPubMed

42.

Vaezi MF. Botulinum toxin in nonachalasia motility disorders: a welcomed therapy in an area with limited therapeutic options. Clin Gastroenterol Hepatol. 2013;11(9):1122–4. https://doi.org/10.1016/j.cgh.2013.04.009.CrossRefPubMed

43.

Marjoux S, Pioche M, Benet T, Lanne JS, Roman S, Ponchon T, et al. Fatal mediastinitis following botulinum toxin injection for esophageal spasm. Endoscopy. 2013;45(Suppl 2 UCTN):E405–6. https://doi.org/10.1055/s-0033-1344908.CrossRefPubMed

44.

Storr M, Allescher HD, Rösch T, Born P, Weigert N, Classen M. Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: a prospective study with long term follow-up. Gastrointest Endosc. 2001;54(6):18ACrossRefPubMed

45.

Sloan JA, Mulki R, Sandhu N, Samuel S, Katz PO. Jackhammer esophagus: symptom presentation, associated distal contractile integral, and assessment of bolus transit. J Clin Gastroenterol. 2018. https://doi.org/10.1097/MCG.0000000000001021.

46.

Khan MA, Kumbhari V, Ngamruengphong S, Ismail A, Chen YI, Chavez YH, et al. Is POEM the answer for management of spastic esophageal disorders? A systematic review and meta-analysis. Dig Dis Sci. 2017;62(1):35–44. https://doi.org/10.1007/s10620-016-4373-1.CrossRefPubMed

47.

Ford AC, Suares NC, Talley NJ. Meta-analysis: the epidemiology of noncardiac chest pain in the community. Aliment Pharmacol Ther. 2011;34(2):172–80. https://doi.org/10.1111/j.1365-2036.2011.04702.x.CrossRefPubMed

48.

Coss-Adame E, Erdogan A, Rao SS. Treatment of esophageal (noncardiac) chest pain: an expert review. Clin Gastroenterol Hepatol. 2014;12(8):1224–45. https://doi.org/10.1016/j.cgh.2013.08.036.CrossRefPubMed

49.

Hershcovici T, Achem SR, Jha LK, Fass R. Systematic review: the treatment of noncardiac chest pain. Aliment Pharmacol Ther. 2012;35(1):5–14. https://doi.org/10.1111/j.1365-2036.2011.04904.x.CrossRefPubMed

50.

Miller LS, Pullela SV, Parkman HP, Schiano TD, Cassidy MJ, Cohen S, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol. 2002;97(7):1640–6. https://doi.org/10.1111/j.1572-0241.2002.05821.x.CrossRefPubMed

51.

Marston AP, Maldonado FJ, Ravi K, Kasperbauer JL, Ekbom DC. Treatment of oropharyngeal dysphagia secondary to idiopathic cricopharyngeal bar: surgical cricopharyngeal muscle myotomy versus dilation. Am J Otolaryngol. 2016;37(6):507–12. https://doi.org/10.1016/j.amjoto.2016.07.006.CrossRefPubMed

52.

Regan J, Murphy A, Chiang M, McMahon BP, Coughlan T, Walshe M. Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders. Cochrane Database Syst Rev. 2014;5:CD009968. https://doi.org/10.1002/14651858.CD009968.pub2.CrossRef

53.

Kelly EA, Koszewski IJ, Jaradeh SS, Merati AL, Blumin JH, Bock JM. Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction. Ann Otol Rhinol Laryngol. 2013;122(2):100–8. https://doi.org/10.1177/000348941312200205.CrossRefPubMedPubMedCentral

54.

Wang YC, Shyu SG, Wu CH, Wang TG. Ultrasound-guided injection of botulinum toxin for cricopharyngeal dysphagia. Am J Phys Med Rehabil. 2018;97:e102–3. https://doi.org/10.1097/PHM.0000000000000959.CrossRefPubMed

55.

Ortiz V, García-Campos M, Sáez-González E, del Pozo P, Garrigues V. A concise review of opioid-induced esophageal dysfunction: is this a new clinical entity? Dis Esophagus. 2018. https://doi.org/10.1093/dote/doy003.

56.

Kahrilas PJ, Pandolfino JE. Treatments for achalasia in 2017: how to choose among them. Curr Opin Gastroenterol. 2017;33(4):270–6. https://doi.org/10.1097/MOG.0000000000000365CrossRefPubMedPubMedCentral

57.

You G, Khan A, Shor J, Forester GP. Rapidly progressive muscle paralysis and acute respiratory failure following endoscopic botulinum toxin injection. ACG Case Rep J. 2016;3(4):e166. https://doi.org/10.14309/crj.2016.139.CrossRefPubMedPubMedCentral

58.

Kahrilas PJ, Bredenoord AJ, Carlson DA, Pandolfino JE. Advances in management of esophageal motility disorders. Clin Gastroenterol Hepatol. 2018;16:1692–700. https://doi.org/10.1016/j.cgh.2018.04.026.CrossRefPubMedPubMedCentral

Title: The Role of Botulinum Toxin Injections for Esophageal Motility Disorders
Authors: Jessica L. Sterling, MD
Ron Schey, MD
Zubair Malik, MD
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Treatment Options in Gastroenterology / Issue 4/2018
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-018-0212-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Pancreatic Cancer and Diabetes Mellitus

Which Patient-Related Factors Determine Optimal Bowel Preparation?

Endoscopic Full-Thickness Defects and Closure Techniques

Selection of EMR and ESD for Laterally Spreading Lesions of the Colon

Gastroduodenal “Dysbiosis”: a New Clinical Entity

Parkinson’s Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage